PMC6198101_01
Image of the clinical course in case 1, a luminal-HER2 type breast cancer patient. (A) The history of breast cancer treatment. (B) The images show (*) when recurrence detected, and (**) radiologically complete remission. Ope = operation; RTx = radiotherapy; CTx = chemotherapy; ETx = endocrine therapy; cCR = clinical complete response; MBC = metastatic breast cancer.
gr1.jpg
PMC6198101_01_gr1.jpg
fig0005
The last follow up was August 2018 and she has survived for 11.5 year after termination of anti-HER2 therapy (Fig. 1).
PMC6198101_02
Image of the clinical course in case 2, a HER2-enriched type breast cancer patient. (A) The history of breast cancer treatment. (B) The images show (*) when recurrence detected, and (**) radiologically complete remission. Scar remained in her right lung because the patient received video assisted thoracic surgery as biopsy from metastatic site.. Op = operation; RTx = radiotherapy; CTx = chemotherapy; cCR = clinical complete response; MBC = metastatic breast cancer
gr2.jpg
PMC6198101_02_gr2.jpg
fig0010
The last follow up was August, 2018 and she has survived for 10 months after termination of anti-HER2 therapy (Fig. 2).
PMC6198101_03
Image of the clinical course in case 3, a HER2-enriched type breast cancer patient. (A) The history of breast cancer treatment. (B) The images show (*) when the patient was diagnosed with MBC, and (**) radiologically complete remission. The patient did not receive surgical recession of tumor region. Op = operation; RTx = radiotherapy; CTx = chemotherapy; cCR = clinical complete response; MBC = metastatic breast cancer.
gr3.jpg
PMC6198101_03_gr3.jpg
fig0015
The last follow up was June 2018 and she has survived for 2 years and a half month after termination of anti-HER2 therapy (Fig. 3).
PMC6198101_04
Image of the clinical course in case 4, a HER2-enriched type breast cancer patient. (A) The history of breast cancer treatment. (B) The images show (*) when the patient was diagnosed with MBC, and (**) radiologically complete remission. The patient received mastectomy and sentinel lymph node biopsy, proving pathological complete response in the left breast. (C) Tapering trastuzumab for termination after maintenance therapy. The dose of trastuzumab was gradually reduced in all patients.. Op = operation; RTx = radiotherapy; CTx = chemotherapy; cCR = clinical complete response; MBC = metastatic breast cancer
gr4.jpg
PMC6198101_04_gr4.jpg
fig0020
The last follow up was July, 2018 and she has survived for 8 months after termination of anti-HER2 therapy (Fig. 4).